New pyrazole-annulated azathioxanthenes as potential intercalators: Synthesis and structure elucidation

Journal of Heterocyclic Chemistry

Volumn 33, Issue 3, 1996, Pages 831-835

  Varvaresou, A ^a   Tsotinis, A ^a   Siatra Papastaikoudi, Th ^a   Calogeropoulou, T ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; INTERCALATING AGENT;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE;

EID: 0029742041     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570330348     Document Type: Article

References (27)

1. B. Pullman, Int. J. Quantum Chem., Quantum Biol. Symp., 13, 95 (1986).
2. B. Pullman, Anthracycline and Anthracenedione-Based Anticancer Agents, J. W. Lown, ed, Elsevier, Amsterdam, 1988.
3. W. D. Wilson, R. L Jones, Intercalation Chemistry, M. S. Whittingham, A. J. Jacobson, eds, Academic Press, New York, 1982, Chapter 14.
4. J. R. Brown, Prog. Med. Chem., 15, 125 (1978).
5. D. J. Patel, S. A. Kozlowski, J. A. Rice, Proc. Natl. Acad. Sci. USA, 78, 3333 (1981).
6. A. Dimarco, F. Arcamone, Arzneim.-Forsch., 25, 368 (1975).
7. J. B. Johnston, L. A. Zwelling, D. Kerrigan, L. S. Lyoyed, and I. R. Gloazer, Biochem. Pharmacol., 32, 2255 (1983).
8. L. A. Zwelling, S. Michaels, L. C. Erickson, R. S. Ungerleider, M. Nichols, and K. W. Krkohn, Biochemistry, 20, 6553 (1981).
9. F. Arcamone, Doxorubicin Anticancer Antibiotics; Academic Press, New York, 1981, pp 1-47
10. P. H. Wiernik, Anthracyclines. Current Status and Development, S. T. Crooke, S. D. Reich, eds, Academic, New York, 1980, pp 273-294.
11. L. Lenaz and J. A. Page, Cancer Treat. Rev., 3, 111 (1976).
12. D. H. Huffman, R. S. Benjamin, and N. R. Bachur, Clin. Pharmacol. Ther., 13, 895 (1972).
13. R. C. Yong, R. F. Ozols, and C. E. Myers, New Engl. J. Med., 305, 139 (1981).
14. K. Handa and S. Sato, Gann, 67, 253 (1976).
15. J. Doroshow and P. Hochstein, Pathology of Oxygen; A. Autor, ed, Academic Press, New York, 1982, pp 245-259
16. J. H. Doroshow, Cancer Res., 43, 460 (1983).
17. E. M. Acton and G. L. Tong, J. Med. Chem., 24, 669 (1981).
18. G. L. Tong, D. W. Henry, and E. M. Acton, J. Med. Chem., 22, 36 (1979).
19. H. D. H. Showalter, J. L. Johnson, J. M. Hoftiezer, W. R. Turner, L M. Werber, W. R. Leopold, J. L. Shillis, R. C. Jackson, and E. F. Elslager, J. Med Chem., 30, 121 (1987).
20. H. D. H. Showalter, M. M. Angelo, E. M. Berman, G. D. Kanter, D. F. Ortwine, S. G. Ross-Kesten, A. D. Sercel, W. R. Turner, L. M. Werbel, D. F. Worth, E. F. Elsager, W. R. Leopold, and J. L. Shillis, J. Med. Chem., 31, 1527 (1988).
21. E. J. Jr. Blanz and F. A. French, J. Med. Chem., 6, 185 (1963).
22. H. D. H. Showalter, J. L. Johnson, and J. M. Hoftiezer, J. Heterocyclic Chem., 23, 1491 (1986).
23. A. Fujimoto, T. Shimizu, and T. Tatsuno, Chem. Pharm. Bull. Japan., 24, 356 (1976).
24. C. E. Bishop and G. W. Morrow, J. Org. Chem., 48, 657 (1983).
25. A. T. Nielsen, R. L. Atkins and W. P. Noms, J. Org. Chem., 44, 1181 (1979)
26. J. C. Hinshaw, W. W. Edwards, C. C. George and R. Gilardi, J. Heterocyclic Chem., 29, 1721 (1992)
27. H. Ritter and H. H. Licht, J. Heterocyclic Chem., 32, 585 (1995).